The type 2 diabetes win with once-weekly glucagon-like peptide-1 (GLP-1) agonist semaglutide by Novo Nordisk A/S in SUSTAIN 7 put pressure of the kind not expected by some analysts on Eli Lilly and Co., whose dulaglutide in the same class – commercialized as Trulicity – came up short in the experiment.